NCT04086602View on ClinicalTrials.gov

Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

February 4, 2020

Study Completion Date

February 4, 2020

Conditions

Healthy VolunteersCryopyrin Associated Periodic Syndrome

Interventions

DRUG

IZD334

Active Drug

DRUG

Placebos

Placebo to Match

Trial Locations (1)

Unknown

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

Inflazome UK Ltd

All Listed Sponsors

lead

Inflazome UK Ltd

INDUSTRY